CC
AGIO icon

Casdin Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Casdin Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25,000
Closed -$1.43M – 32
2017
Q4 		$1.43M Buy
+25,000
New +$1.57M 0.35% 27
2016
Q1 		– Sell
-5,000
Closed -$325K – 27
2015
Q4 		$325K Buy
+5,000
New +$328K 0.29% 30

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Casdin Capital's AGIO Position: Q3 2025 in Review

Casdin Capital sold out of Agios Pharmaceuticals (AGIO) in Q3 2025, closing a stake of 100,000 shares — an estimated $3.33M sold.

Casdin Capital first reported a position in AGIO in Q4 2015 and held it in 30 quarters. The position peaked at $119M in Q2 2021. 221 funds tracked by Wall St. Rank hold AGIO as of Q3 2025.

  • Casdin Capital reported no remaining Agios Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Casdin Capital sold 100,000 Agios Pharmaceuticals shares in Q3 2025, an estimated $3.33M.
  • Casdin Capital first reported a position in Agios Pharmaceuticals in Q4 2015 and held it in 30 quarters.
  • Casdin Capital's Agios Pharmaceuticals position peaked at $119M in Q2 2021.
  • 221 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2025.

Based on Casdin Capital's 13F filing for Q3 2025, filed 14 Nov 2025.